Telix Pharmaceuticals (TLX) H2 2025 earnings summary

Executive summary

• Achieved 56% revenue growth to $804 million in FY 2025, marking the third consecutive year of double-digit growth and surpassing guidance, driven by strong commercial execution, precision medicine, and successful product launches including Illuccix and Gozellix.

• Precision medicine revenue rose 22% year-over-year to $622 million, with Illuccix and Gozellix launches as key contributors.

• Maintained a solid cash position of $142 million despite significant R&D and infrastructure investments, supporting continued strategic expansion.

• Strategic focus on expanding the therapeutics pipeline, global market access, and launching new products Pixclara and Zircaix.

• Multiple pivotal and late-stage clinical trials underway, with key data readouts and regulatory submissions expected in 2026.

Financial highlights

• EBITDA improved to $216 million, driven by demand for Illuccix and Gleolan, while adjusted EBITDA was $39.5 million, reflecting increased investment in growth initiatives.

• Gross margin remained stable at 64%, with gross profit rising to $426 million.

• Operating profit was $30 million, with a net loss after tax of $7 million due to higher finance costs and R&D investment.

• Generated $206 million in operational cash flow, with net positive operating cash flow of $35 million after contingent payments.

• General and administration expenses decreased to 12% of revenue from 17% last year, reflecting scale efficiencies.

Outlook and guidance

• FY 2026 revenue guidance set at $950 million–$970 million, with up to 25% growth in precision medicine and a full year of RLS revenue.

• R&D investment for FY 2026 projected at $200 million–$240 million, focused on therapeutic development and pipeline expansion.

• Anticipates multiple regulatory submissions and product launches, with 2026 positioned as an inflection year.

• Plans to reinvest the majority of earnings into R&D, commercial expansion, and infrastructure through 2027.